Carregant...

Functional RNAi Screens Define Distinct Protein Kinase Vulnerabilities in EGFR-Dependent HNSCC Cell Lines

The inhibitory epidermal growth factor receptor (EGFR) antibody, cetuximab, is an approved therapy for head and neck squamous cell carcinoma (HNSCC). Despite tumor response observed in some HNSCC patients, cetuximab alone or combined with radio- or chemotherapy fails to yield long-term control or cu...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Pharmacol
Autors principals: Hinz, Trista K., Kleczko, Emily K., Singleton, Katherine R., Calhoun, Jacob, Marek, Lindsay A., Kim, Jihye, Tan, Aik Choon, Heasley, Lynn E.
Format: Artigo
Idioma:Inglês
Publicat: The American Society for Pharmacology and Experimental Therapeutics 2019
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7385532/
https://ncbi.nlm.nih.gov/pubmed/31554698
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/mol.119.117804
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!